Relay Therapeutics, Inc.
NASDAQRelay Therapeutics heads into its Q2 earnings release tonight with a striking divergence: short sellers have been covering aggressively, even as the analyst community has turned unanimously bullish. The short-interest picture tells the clearest story. Bearish positioning has collapsed by roughly 15% over the past month, dropping from a peak near 47 million shares in mid-July to…
RLAY short interest surges 21.2% in a week to 26.3% of float, driven by clinical-stage biotech volatility and bearish positioning ahead of pipeline catalysts.
Snapshot as of 7 Aug 2026
Relay Therapeutics heads into its Q2 earnings release tonight with a striking divergence: short sellers have been covering aggressively, even as the analyst community has turned unanimously bullish. The short-interest…
Relay Therapeutics exits its Q1 earnings week with an unusual split: the Street just raised price targets across the board, yet shorts are adding and the stock is down 7% on the week. The analyst move this week is the…
Relay Therapeutics heads into its Q1 2026 earnings print today carrying one of the sharpest tensions in small-cap biotech: 16.3% of the free float sold short, yet not a single analyst holds anything other than a…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RLAY — free to start on ORTEX.
Sign up for free →Open RLAY on ORTEX